老年H型高血压病人合并肌少症情况及其影响因素研究

doi:10.3969/j.issn.1003-9198.2024.07.005

摘要/Abstract

摘要： 目的探讨老年H型高血压病人肌少症(sarcopenia,SA)的患病率及其影响因素,为预防和早期干预SA提供参考依据。方法选取2021年3—6月参加体检的≥60岁的191例H型高血压病人,根据2019年亚洲肌少症工作组的SA诊断标准分为SA组(n=93)和非SA组(n=98)。收集并比较2组病人的一般资料及实验室检查结果,采用二元 Logistic 回归分析老年H型高血压病人发生SA的影响因素。结果 SA组的腰围、颈围、小腿围以及BMI水平均低于非SA组(P＜0.01),年龄、收缩压、血小板计数、HDL-C水平均高于非SA组(P＜0.01)。体形消瘦者、体形正常者、超重者和肥胖者SA检出率分别为100%、72.2%、23.4%和6.7%,SA检出率随 BMI增加而降低(χ²_趋势 =59.78,P＜0.001)。Logistic 回归分析显示,BMI高(OR=0.682,95%CI:0.555～0.838)、小腿围粗(OR=0.621,95%CI:0.480～0.805)是SA的保护因素(P<0.05),血小板计数高(OR=1.012,95%CI:1.004～1.019)和HDL-C水平高(OR=3.026,95%CI:1.105～8.283)是SA的危险因素(P<0.05)。结论老年H型高血压病人SA患病率高。血小板计数、HDL-C、BMI和小腿围是H型高血压病人发生SA的影响因素。

关键词: H型高血压, 肌少症, 老年人

Abstract: Objective To explore the prevalence and influencing factors of sarcopenia(SA)in the elderly patients with H-type hypertension, and to provide reference for prevention and early intervention. Methods A total of 191 elderly patients(aged ≥60 years old) with H-type hypertension who received medical examinations from March to June 2021 were enrolled. According to the diagnostic criteria of SA of Asian Working Group for Sarcopenia 2019(AWGS), the patients were divided into the SA group(n=93) and the non-SA group(n=98). General information and laboratory test results were collected and compared between the two groups. Binary Logistic regression analysis was used to analyze the influencing factors for SA in the elderly patients with H-type hypertension. Results The waist circumference, neck circumference, calf circumference and BMI were significantly lower and the levels of age, diastolic blood pressure, platelet count and high-density lipoprotein cholesterol(HDL-C)were higher in the SA group than those in the non-SA group(P<0.01). The SA detection rates were 100%, 72.2%, 23.4% and 6.7% in the emaciated, normal-sized, overweight and obese individuals, respectively. The SA detection rate decreased with the increase of BMI (χ² _trend= 59.78, P < 0.001). Logistic regression analysis showed that BMI(OR=0.682,95%CI:0.555-0.838)and calf circumference(OR=0.621,95%CI:0.480-0.805)were the protective factors for the development of SA(P<0.05), and platelet counts(OR=1.012,95%CI:1.004-1.019)and HDL-C levels(OR=3.026,95%CI:1.105-8.283) were the risk factors for SA in the elderly patients with H-type hypertension(P<0.05). Conclusions The prevalence of SA in the elderly patients with H-type hypertension is high. Platelet count, HDL-C, BMI and calf circumference are the influencing factors for SA in the elderly patients with H-type hypertension.

Key words: H-type hypertension, sarcopenia, aged

中图分类号:

R 544.1

杜雨恬, 廖欣怡, 张素琼, 石磊, 程道梅. 老年H型高血压病人合并肌少症情况及其影响因素研究[J]. 实用老年医学, 2024, 38(7): 665-668.

DU Yutian, LIAO Xinyi, ZHANG Suqiong, SHI Lei, CHENG Daomei. Prevalence and influencing factors of sarcopenia in elderly patients with H-type hypertension[J]. Practical Geriatrics, 2024, 38(7): 665-668.

参考文献

[1] CHEN L K, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307.
[2] 崔华, 王朝晖, 吴剑卿, 等. 老年人肌少症防控干预中国专家共识(2023) [J] . 中华老年医学杂志, 2023, 42(2): 144-153.
[3] CANNATARO R, CARBONE L, PETRO J L, et al. Sarcopenia: etiology, nutritional approaches, and miRNAs[J]. Int J Mol Sci, 2021, 22(18): 9724.
[4] TIELAND M, TROUWBORST I, CLARK B C. Skeletal muscle performance and ageing[J]. J Cachexia Sarcopenia Muscle, 2018, 9(1): 3-19.
[5] GAO K, CAO L F, MA W Z, et al. Association between sarcopenia and cardiovascular disease among middle-aged and older adults: findings from the China health and retirement longitudinal study[J]. E Clinical Medicine, 2022, 44: 101264.
[6] 刘娟, 丁清清, 周白瑜,等. 中国老年人肌少症诊疗专家共识(2021)[J]. 中华老年医学杂志, 2021,40(8):943-952.
[7] 曹丰,陈鲁原,陈伟伟,等.中国老年高血压管理指南2023[J].中华高血压杂志,2023,31(6):508-538.
[8] 李东晓,张尧,张宏武, 等.高同型半胱氨酸血症的诊断、治疗与预防专家共识[J].罕少疾病杂志,2022,29(6):1-4.
[9] 吕明月,王静,赵娜,等.肌少症与H型和非H型老年高血压的相关性临床研究[J].内蒙古医学杂志,2023,55(2):129-133,137.
[10] PANG H, FU Q, CAO Q,et al. Sex differences in risk factors for stroke in patients with hypertension and hyperhomocysteinemia[J]. Sci Rep,2019,9(1):14313.
[11] MAJUMDER A,SINGH M, BEHERA J, et al. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury[J]. Am J Physiol Cell Physiol,2018, 315(5): C609-C622.
[12] MAJUMDER A, BEHERA J, JEREMIC N, et al. Hypermethylation: causes and consequences in skeletal muscle myopathy[J]. J Cell Biochem Suppl, 2017, 118(8): 2108-2117.
[13] RICHTER-STRETTON G L, FENNING A S, VELLA R K. Skeletal muscle-a bystander or influencer of metabolic syndrome?[J]. Diabetes Metab Syndr,2020, 14(5): 867-875.
[14] WIEDMER P, JUNG T, CASTRO J P, et al. Sarcopenia-molecular mechanisms and open questions[J]. Ageing Res Rev, 2021, 65: 101200.
[15] NISHIKAWA H, YOH K, ENOMOTO H, et al. Calf circumference as a useful predictor of sarcopenia in patients with liver diseases[J]. In Vivo, 2020, 34(5): 2561-2569.
[16] DU Y, TAO S, OH C, et al. The function of body mass index in the older with osteosarcopenia: a systematic review and meta-analysis[J]. J Obes Metab Syndr, 2023, 32(1): 77.
[17] ZHAO H, LI Y, ZHANG M, et al. Blood lipid levels in patients with osteopenia and osteoporosis: a systematic review and meta-analysis[J]. J Bone Miner Metab,2021, 39(3): 510-520.
[18] KIM J, KIM H S, LEE H S, et al. The relationship between platelet count and bone mineral density: results from two independent population-based studies[J]. Arch Osteoporos, 2020, 15(1): 43.
[19] AJOOLABADY A, PRATICO D, VINCIGUERRA M,et al. Inflammaging: mechanisms and role in the cardiac and vasculature[J]. Trends Endocrinol Metab,2023,34(6):373-387.
[20] LINGE J, HEYMSFIELD S B, DAHLQVIST L O. On the definition of sarcopenia in the presence of aging and obesity-initial results from UK biobank[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(7): 1309-1316.